Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Anna Wolska-Washer, Piotr Smolewski & Tadeusz Robak. (2021) Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma. Expert Opinion on Pharmacotherapy 22:9, pages 1203-1215.
Read now
Read now
Helen Ma, Owen A. O’Connor & Enrica Marchi. (2019) New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. Expert Review of Hematology 12:3, pages 137-146.
Read now
Read now
Marc Sorigue, Elisa Orna & Juan-Manuel Sancho. (2018) Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. Leukemia & Lymphoma 59:11, pages 2602-2611.
Read now
Read now
Natalie Galanina, Adam Petrich & Chadi Nabhan. (2016) The evolving role of lenalidomide in non-Hodgkin lymphoma. Leukemia & Lymphoma 57:7, pages 1507-1516.
Read now
Read now
Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan & Manisha Bhutani. (2015) Expanding role of lenalidomide in hematologic malignancies. Cancer Management and Research 7, pages 105-119.
Read now
Read now
Michael Dickinson & Henry Miles Prince. (2014) Emerging drugs for T-cell lymphoma. Expert Opinion on Emerging Drugs 19:2, pages 201-213.
Read now
Read now
Georg Hopfinger, Robert Griessl, Eveline Sifft, Ninon Taylor, Lukas Kenner, Richard Greil & Olaf Merkel. (2012) Novel treatment avenues for peripheral T-cell lymphomas. Expert Opinion on Drug Discovery 7:12, pages 1149-1163.
Read now
Read now
Articles from other publishers (36)
Robert Stuver, Zachary D. Epstein-Peterson & Steven M. Horwitz. (2023) Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas. Haematologica 108:12, pages 3244-3260.
Crossref
Crossref
Robert Stuver & Alison J. Moskowitz. (2023) Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma. Cancers 15:3, pages 589.
Crossref
Crossref
Emanuele Cencini, Alberto Fabbri, Bianca Mecacci & Monica Bocchia. (2021) Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas. World Journal of Clinical Oncology 12:10, pages 882-896.
Crossref
Crossref
Neha Mehta‐Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan, Peggy Lynch, Paul A. Hamlin, John Leonard, Matthew J. Matasar, Patricia L. Myskowski, Evan Marzouk, Sumithra Nair, Tamir Sholklapper, Veena Minnal, Maria L. Palomba, James Vredenburgh, Anita Kumar, Ariela Noy, David J. Straus, Andrew D. Zelenetz, Heiko Schoder, Jurgen Rademaker, Wendy Schaffer, Natasha Galasso, Nivetha Ganesan & Steven M. Horwitz. (2021)
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase
I
studies with expansion cohorts
. American Journal of Hematology 96:10, pages 1211-1222.
Crossref
Crossref
Jehan Dupuis & Franck Morschhauser. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas
115
128
.
N. Nora Bennani & Stephen M. Ansell. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas
105
114
.
Enrica Marchi, Ahmed Sawas, Helen Ma, Luigi Scotto & Francesca Montanari. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas
367
377
.
Danilo Fiore, Luca Vincenzo Cappelli, Alessandro Broccoli, Pier Luigi Zinzani, Wing C. Chan & Giorgio Inghirami. (2020) Peripheral T cell lymphomas: from the bench to the clinic. Nature Reviews Cancer 20:6, pages 323-342.
Crossref
Crossref
Shekeab Jauhari & Matt McKinney. 2020. Novel Therapeutics for Rare Lymphomas. Novel Therapeutics for Rare Lymphomas
209
220
.
Preethi Ramachandran, Alok Aggarwal & Jen Chin Wang. 2019. Peripheral T-cell Lymphomas. Peripheral T-cell Lymphomas.
Anna Gerbe, Melissa Alame, Olivier Dereure, Samia Gonzalez, Luc Durand, Ariane Tempier, Laura De Oliveira, Alicia Tourneret, Valérie Costes-Martineau, Valère Cacheux & Vanessa Szablewski. (2019) Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior. Virchows Archiv 475:2, pages 163-174.
Crossref
Crossref
Robert N. Stuver, Niloufer Khan, Marc Schwartz, Mark Acosta, Massimo Federico, Christian Gisselbrecht, Steven M. Horwitz, Frederik Lansigan, Lauren C. Pinter‐Brown, Barbara Pro, Andrei R. Shustov, Francine M. Foss & Salvia Jain. (2019) Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry. American Journal of Hematology 94:6, pages 641-649.
Crossref
Crossref
Emanuele Cencini, Alberto Fabbri, Anna Sicuranza & Monica Bocchia. (2019) Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma. Leukemia Research 77, pages 5-7.
Crossref
Crossref
Davide BrocchiAlessandro Broccoli, Dai Chihara, Michelle A. Fanale & Pier Luigi Zinzani. 2019. Nachhaltigkeit und soziale Ungleichheit. Nachhaltigkeit und soziale Ungleichheit
227
244
.
Alessandro Broccoli, Lisa Argnani & Pier Luigi Zinzani. (2017) Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treatment Reviews 60, pages 120-129.
Crossref
Crossref
Alessandro Broccoli & Pier Luigi Zinzani. (2017) Peripheral T-cell lymphoma, not otherwise specified. Blood 129:9, pages 1103-1112.
Crossref
Crossref
Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard Lutes, Andy Chi & Stefano Pileri. (2016) Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Critical Reviews in Oncology/Hematology 99, pages 214-227.
Crossref
Crossref
Jae-Cheol Jo, Yunsuk Choi, Ho-Jin Shin, Sung Nam Yhim, Ho Sup Lee, Won-Sik Lee, Ji-Hyun Lee, Hawk Kim & Sung Yong Oh. (2016) Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). Annals of Hematology 95:4, pages 619-624.
Crossref
Crossref
T.E. Witzig, G.S. Nowakowski, T.M. Habermann, A. Goy, F.J. Hernandez-Ilizaliturri, A. Chiappella, U. Vitolo, N. Fowler & M.S. Czuczman. (2015) A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of Oncology 26:8, pages 1667-1677.
Crossref
Crossref
Chan Yoon CheahYasuhiro OkiMichelle A. Fanale. (2015) Novel Treatments for T-Cell Lymphoma. American Society of Clinical Oncology Educational Book:35, pages e468-e478.
Crossref
Crossref
Athena Kritharis, Michael Coyle, Jaya Sharma & Andrew M. Evens. (2015) Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood 125:16, pages 2471-2476.
Crossref
Crossref
Marco Foppoli & Andrés J. M. Ferreri. (2014) Gamma‐delta t‐cell lymphomas. European Journal of Haematology 94:3, pages 206-218.
Crossref
Crossref
Sarah Barton, Eliza A. Hawkes, David Cunningham, Clare Peckitt, Sue Chua, Andrew Wotherspoon, Ayoma Attygalle, Alan Horwich, Mike Potter, Mark Ethell, Claire Dearden, Mary Gleeson & Ian Chau. (2014)
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐
GEM
‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma
. European Journal of Haematology 94:3, pages 219-226.
Crossref
Crossref
Ethan Toumishey, Angeli Prasad, Greg Dueck, Neil Chua, Daygen Finch, James Johnston, Richard van der Jagt, Doug Stewart, Darrell White, Andrew Belch & Tony Reiman. (2015) Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 121:5, pages 716-723.
Crossref
Crossref
Bertrand Coiffier, Massimo Federico, Dolores Caballero, Claire Dearden, Franck Morschhauser, Ulrich Jäger, Lorenz Trümper, Emanuele Zucca, Maria Gomes da Silva, Ruth Pettengell, Eckhart Weidmann, Francesco d’Amore, Hervé Tilly & Pier Luigi Zinzani. (2014) Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treatment Reviews 40:9, pages 1080-1088.
Crossref
Crossref
Alessandro Broccoli, Cinzia Pellegrini, Monica Celli, Lisa Argnani, Claudio Agostinelli, Stefano Pileri & Pier Luigi Zinzani. (2014) Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. Clinical Lymphoma Myeloma and Leukemia 14:4, pages e119-e122.
Crossref
Crossref
R Briski, A L Feldman, N G Bailey, M S Lim, K Ristow, T M Habermann, W R Macon, D J Inwards, J P Colgan, G S Nowakowski, M S Kaminski, T E Witzig, S M Ansell & R A Wilcox. (2014) The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer Journal 4:5, pages e214-e214.
Crossref
Crossref
Andrew M. Intlekofer & Anas Younes. (2014) From empiric to mechanism-based therapy for peripheral T cell lymphoma. International Journal of Hematology 99:3, pages 249-262.
Crossref
Crossref
Georg Hopfinger, Thomas Nösslinger, Alois Lang, Werner Linkesch, Thomas Melchardt, Lukas Weiss, Alexander Egle & Richard Greil. (2014) Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of Hematology 93:3, pages 459-462.
Crossref
Crossref
Alberto Fabbri, Emanuele Cencini, Alice Pietrini, Alessandro Gozzetti, Marzia Defina, Giulia Fontanelli, Maria Antonietta Mazzei, Luca Volterrani & Monica Bocchia. (2012) Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T‐cell lymphoma: report of a case with long‐term follow‐up. Hematological Oncology 31:4, pages 213-217.
Crossref
Crossref
Franck Morschhauser, Olivier Fitoussi, Corinne Haioun, Catherine Thieblemont, Hang Quach, Richard Delarue, Sylvie Glaisner, Jean Gabarre, André Bosly, John Lister, Ju Li & Bertrand Coiffier. (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. European Journal of Cancer 49:13, pages 2869-2876.
Crossref
Crossref
Koppany Visnyei, Michael L. Grossbard & Ilan Shapira. (2013) Hepatosplenic γδ T-cell Lymphoma: An Overview. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 360-369.
Crossref
Crossref
Yoshihiro Torimoto, Kazuya Sato, Katsuya Ikuta, Toshiaki Hayashi, Yasuo Hirayama, Junki Inamura, Hajime Kobayashi, Ryoji Kobayashi, Kyuhei Koda, Mitsutoshi Kurosawa, Akio Mori, Shuichi Ota, Hajime Sakai, Akio Shigematsu, Motohiro Shindo, Hitoshi Shinzaki, Fumihiko Takahashi, Rishu Takimoto, Junji Tanaka, Satoshi Yamamoto, Yutaka Kohgo & Takashi Fukuhara. (2013) A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group. International Journal of Hematology 98:2, pages 171-178.
Crossref
Crossref
M. Dreyling, C. Thieblemont, A. Gallamini, L. Arcaini, E. Campo, O. Hermine, J.C. Kluin-Nelemans, M. Ladetto, S. Le Gouill, E. Iannitto, S. Pileri, J. Rodriguez, N. Schmitz, A. Wotherspoon, P. Zinzani & E. Zucca. (2013) ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Annals of Oncology 24:4, pages 857-877.
Crossref
Crossref
Jean Yared & Amy Kimball. (2013) The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: A review of the literature and new perspectives. Cancer Treatment Reviews 39:1, pages 51-59.
Crossref
Crossref
Kerry J. Savage. (2011) Update: Peripheral T-Cell Lymphomas. Current Hematologic Malignancy Reports 6:4, pages 222-230.
Crossref
Crossref